



Immuno-Biological Laboratories Co., Ltd.

References

[10777 Gd-IgA1 \(KM55\) Anti-Human Rat IgG MoAb - IBL](#)

No.	Field	Keywords	Published	Title
1	Dermatology	Nephritis, Vasculitis	2019	Galactose deficient IgA1 (GD-IgA1) in skin and serum from patients with skin-limited and systemic IgA Vasculitis. Neufeld M et al. J Am Acad Dermatol. 2019 Mar 19. pii: S0190-9622(19)30443-8.
2	Nephrology	MEST-C, Herramientas	2021	Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression. Martín-Penagos L et al. Nefrologia. May-Jun 2021;41(3):311-320.
3	Nephrology	Alport syndrom	2021	Utility of glomerular Gd-IgA1 staining for indistinguishable cases of IgA nephropathy or Alport syndrome. Ishiko S et al. Clin Exp Nephrol. 2021 Mar 20.
4	Nephrology	Tg2576	2004	Abeta N-terminal-end specific antibody reduced beta-amyloid in Alzheimer-model mice. Horikoshi Y et al. Biochem Biophys Res Commun. 2004 Dec 10;325(2):384-7.
5	Nephrology	Abeta42	2004	Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Horikoshi Y et al. Biochem Biophys Res Commun. 2004 Jul 2;319(3):733-7.
6	Nephrology	SphK,	2011	BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. Takasugi N et al. J Neurosci. 2011 May 4;31(18):6850-7.
7	Nephrology	App cleavage	2006	BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. Nishitomi K et al. J Neurochem. 2006 Dec;99(6):1555-63.
8	Nephrology	Soybean,	2019	Oral Immunization with Soybean Storage Protein Containing Amyloid-β 4-10 Prevents Spatial Learning Decline. Kawarabayashi T et al. J Alzheimers Dis. 2019;70(2):487-503.
9	Nephropathy	Dietary	2019	Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer's disease. Wakabayashi T et al. Mol Neurodegener. 2019 Apr 12;14(1):15.
10	Nephropathy	24B3,	2017	A Toxic Conformer of Aβ42 with a Turn at 22-23 is a Novel Therapeutic Target for Alzheimer's Disease. Izuo N et al. Sci Rep. 2017 Sep 18;7(1):11811.
11	Nephropathy	CSF,	2012	Altered γ-secretase activity in mild cognitive impairment and Alzheimer's disease. Kakuda N et al. EMBO Mol Med. 2012 Apr;4(4):344-52.

Distributed by:



Immuno-Biological Laboratories, Inc.
8201 Central Ave NE, Suite P
Minneapolis, MN 55432

Toll-Free: 888-523-1246
Email: info@IBL-America.com
Web: www.IBL-America.com